Correction To: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease: Results from a Phase 1 Randomized Trial
Overview
Overview
Journal
Inflamm Bowel Dis
Publisher
Oxford University Press
Specialty
Gastroenterology
Date
2022 Apr 2
PMID
35366308
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.